Optometrists in Clay, NY Accepting Medicare
4 Optometrists found. Showing 1 - 4
 Dr. Howard Jeffrey Kass, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 4081 Route 31, Sears Optical, Clay, NY 13041 Phone: 315-652-4825 |
 D&b Optometry Associates Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 4081 Route 31, Sears Optical, Clay, NY 13041 Phone: 315-652-4818 Fax: 315-652-4819 |
Dr. Anthony Mondo, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4160 Route 31, Clay, NY 13041 Phone: 315-546-0393 Fax: 315-546-0393 |
Mondo Optical Optometrist Medicare: Medicare Enrolled Practice Location: 4160 Route 31, Suite 100a, Clay, NY 13041 Phone: 315-546-0393 Fax: 315-546-0395 |
News Archive
DOD to investigate mental health care at Camp Lejeune, also will stock morning-after pill
The Associated Press reports that, according to Rep. Walter Jones, R-N.C., "The Defense Department will investigate complaints of substandard mental health care for Marines at Camp Lejeune. ... Public questions about the quality of mental health care provided by a private contractor at the base were raised last year by the September firing of Dr. Kernan Manion, a brain trauma specialist who had complained to commanders about poor facilities, inadequate care programs and weak security.
Lannett CEO to participate in NYSE opening bell ringing ceremony
Lannett Company, Inc. (NYSE AMEX: LCI) today announced that President and Chief Executive Officer Arthur Bedrosian will ring the opening bell at the New York Stock Exchange at 9:30 a.m. Eastern on Monday, November 23, 2009.
UM SOM Dean E. Albert Reece, UMMS President and CEO Robert Chrencik named recipients of 'Speaker's Medallion'
The Maryland House of Delegates and House Speaker Michael E. Busch, has announced that University of Maryland School of Medicine Dean E. Albert Reece, MD, PhD, MBA and University of Maryland Medical System President and CEO Robert Chrencik, MBA, are recipients of the "Speaker's Medallion," the highest honor given to the public by the leader of the Maryland House of Delegates.
Genentech announces that Phase III CLL11 study meets primary endpoint
Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.
› Verified 1 days ago
Optometrists
Physical Therapists
Occupational Therapists
Speech-Language Pathologists